Life Sciences

12 Aug 2021  |  North America  |  Market Research

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2019 that centered around the state of their laboratories in 2019 and their expectations for 2020. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year...

The immunoassay and clinical chemistry market is the highest share contributor for the total in vitro diagnostics (IVD) market. Globally valued at $28.7 billion in 2019, this market segment contributes 37.6% of the total IVD market of $76.3 billion. Within the high-medium to low analyzer segment, there are over 40 companies globally. Of these, 14 c...

Today, the journey of starting a family does not look the way it did fifty years ago, and people are turning to fertility services for help. 1 in 8 couples in the United States experience pregnancy-related difficulties that fertility treatments can address. Key market drivers include the increasing rate of obesity causing deterred ovulation in wom...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2018 that centered around the state of their laboratories in 2018 and their expectations for 2019. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year...